TLR8 and breast carcinoma: Additionally, in breast cancer there are currently several clinical trials assessing efficacy of TLR7/8 agonists (TLR8, VTX-2337 and cyclophosphamide, NCT02650635; TLR7, imiquimod, cyclophosphamide, and radiotherapy) [57–59].